ACAAI Board Practice Exam 2026 – The All-in-One Resource for Exam Success!

The TREC assay, which stands for T-cell receptor excision circles assay, is specifically utilized in the diagnosis of certain primary immunodeficiencies, particularly Severe Combined Immunodeficiency (SCID). The assay detects the presence of TREC, which are byproducts of T-cell receptor gene rearrangement during T-cell development. A low or absent level of TRECs is indicative of a reduced number of T-cells, which occurs in conditions like SCID.

Additionally, the TREC assay can be utilized to screen for other immunodeficiencies, such as those associated with 22q11 deletion syndromes, which can lead to a variety of health issues, including immune dysfunction. Trisomy 21, or Down syndrome, can also lead to immunological challenges, and while it isn’t a direct target of the TREC assay, patients often exhibit low T-cell counts similar to those seen in SCID, warranting prenatal or newborn screening approaches.

This focus on screening for SCID and associated immunodeficiencies through the TREC assay highlights its significance in early detection and intervention for severe immune disorders, which is essential for improving patient outcomes.